Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh A. Huseni, Michael B. Atkins et al. · Nature Medicine · 2018
Cited by 1,254 works. doi:10.1038/s41591-018-0053-3
Authors
- David F. McDermott
- Mahrukh A. Huseni
- Michael B. Atkins
- Robert John Motzer
- Brian I. Rini
- Bernard J. Escudier
- Lawrence H. Fong
- Richard Wayne Joseph
- Sumanta Kumar Pal
- James Andrew Reeves
- Mario Sznol
- John Daniel Hainsworth
- W. Kimryn Rathmell
- Walter Michael Stadler
- Thomas E. Hutson
- Martin Eric Gore
- Alain Ravaud
- Sergio Bracarda
- Cristina Suárez
- Riccardo Danielli
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- edgeR : a Bioconductor package for differential expression analysis of digital gene expression data
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Inflammation and cancer
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma